Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics
14 déc. 2023 11h03 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The breast cancer drugs market size is set to to...
Europe Breast and Prostate Cancer Diagnostics Industry is estimated to reach US$ 5,030.1 Million by 2033 Amid Growing Research on Biomarkers | FMI Study
11 déc. 2023 05h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Europe breast and prostate cancer diagnostics industry is estimated to reach US$ 4,041.5 million in 2023 and US$ 5,030.1 million by 2033. Over the...
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
08 déc. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
08 déc. 2023 14h00 HE
|
Seno Medical
San Antonio, Texas, Dec. 08, 2023 (GLOBE NEWSWIRE) -- A limited feasibility study presented at this year’s San Antonio Breast Cancer Symposium (SABCS) found that Seno Medical’s Imagio® Breast...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
06 déc. 2023 08h30 HE
|
Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
05 déc. 2023 22h52 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
05 déc. 2023 13h33 HE
|
Arvinas Inc.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the...
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
05 déc. 2023 12h27 HE
|
Olema Oncology
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...
PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium
05 déc. 2023 07h00 HE
|
PreludeDx
In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
01 déc. 2023 11h02 HE
|
Celcuity Inc.
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...